Human exposure to aluminium is burgeoning with significant implications for human health. Aluminium based adjuvants [ABAs] are effective and cheap but are they safe? Confirmation of their safety remains to be addressed and will only come from further research on their biological activities at injection sites and beyond. All ABAs currently in use in vaccination and sub-cutaneous immunotherapy require further validation of their safety... Burgeoning knowledge regarding the biological activities of ABAs now dictates that their safety should be evaluated independently of their presence in vaccine formulations.
Comments are closed.
|
Archives
March 2021
|